107922-63-4

Upstream product

• 577-59-3 2-acetylnitrobenzene 
• 100-63-0 phenylhydrazine 

Downstream Products

• 1296204-09-5 dimethyl 2,6-dimethyl-4-{3-[2-nitrophenyl]-1-phenyl-1H-pyrazol-4-yl}-1,4-dihydropyridine-3,5-dicarboxylate 
• 1296204-29-9 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(3-(2-nitrophenyl)-1-phenylpyrazol-4-yl)pyridine 
• 1296204-31-3 2,6-dimethyl-3,5-diethoxycarbonyl-4-(3-(2-nitrophenyl)-1-phenylpyrazol-4-yl)pyridine 
• 103688-05-7 2-phenyl-2H-pyrazolo<4,3-c>quinoline 
• 863641-94-5 ethyl (E)-3-(3-(2-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)acrylate 
• 863641-95-6 ethyl (E)-3-(3-(2-aminophenyl)-1-phenyl-1H-pyrazol-4-yl)propanoate 
• 863641-59-2 3-(2-nitrophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 863641-48-9 3-(2-nitrophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid 
• 863641-70-7 2-phenylpyrazolo[4,3-c]quinolin-4(5H)-one 
• 863641-82-1 2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-amine 
• 863641-91-2 2-phenyl-2H-pyrazolo[4,3-c]quinolin-4(5H)-thione 

Relevant academic research and scientific papers

Molybdenum-catalyzed synthesis of nitrogenated polyheterocycles from nitroarenes and glycols with reuse of waste reduction byproduct

A novel domino reduction/imine formation/intramolecular cyclization/oxidation for the efficient synthesis of pyrrolo(indolo)[1,2-a]quinoxalines and pyrrolo(indolo)-[3,2-c]-quinolines from readily available nitrobenzenes and glycols is reported. The process utilizes the carbonyl byproduct of the initial dioxomolybdenum(VI)-catalyzed reduction of nitroaromatics with glycols as a reagent for the imine generation. This method represents the first sustainable domino reaction for the preparation of biologically relevant heterocycles that internally incorporates the waste formed in the first step to the final product.

Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents

Three series of 1,3-diaryl pyrazole derivatives bearing aminoguanidine or furan-2-carbohydrazide moieties have been synthesized, characterized and evaluated for antibacterial and anti-inflammatory activities. Most of the synthesized compounds showed potent inhibition of several Gram-positive bacterial strains (including multidrug-resistant clinical isolates) and Gram-negative bacterial strains with minimum inhibitory concentration values in the range of 1-64 μg/mL. Compounds 6g, 6l and 7l presented the most potent inhibitory activity against Gram-positive bacteria (e.g. Staphylococcus aureus 4220), Gram-negative bacteria (e.g. Escherichia coli 1924) and the fungus, Candida albicans 7535, with minimum inhibitory concentration values of 1 or 2 μg/mL. Compared with previous studies, these compounds exhibited a broad spectrum of inhibitory activity. Furthermore, compound 7l showed the greatest anti-inflammatory activity (93.59% inhibition, 30 min after intraperitoneal administration), which was more potent than the reference drugs ibuprofen and indomethacin.

New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists

In this paper we report the synthesis and biological evaluation of a new class of 2-phenyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-4-ones as A3 adenosine receptor antagonists. We designed a new route based on the Kira-Vilsmeier reaction for the syn

Structure-activity relationships of antimalarial indoloquinolines

Structure-activity relationships have been ascertained and chemical metodology developed for a series of antimalarial 3-chloroindoloquinoline-5-oxides.The basic side chain as well as the ring N-oxide are critical for antimalarial activity as is a bromine or chlorine in position 3.Substitution at positions 7,8,9,10 in not essential, although the most potent analog in our studies was the 8-nitro compound 4vv. indoloquinolines / antimalarial agents